On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading
CR-prize-study-tor-2024 At the end of 2024, Congress was poised to enact a 1547 page appropriations bill with bipartisan support. Elon Musk blew up the bill, mounting an attack on the bill through X, the social media platform he controls. The… Continue Reading
rfkjr-kei-13June2025-xtandi June 13, 2025 Robert F. Kennedy, Jr. Secretary U.S. Department of Health and Human Services 200 Independence Ave SW, Washington, DC 20201 RE: Request for issuance of authorization and consent to use federal rights in three patents to supply… Continue Reading
European Commission (DG 1) note on the WHO’s Revised Drug Strategy EUROPEAN COMMISSION DIRECTORATE GENERAL 1 EXTERNAL RELATIONS: COMMERCIAL POLICY AND RELATIONS WITH NORTH AMERICA. THE FAR EAST, AUSTRALIA AND NEW ZEALAND Directorate D -Sectoral trade questions,… Continue Reading
On June 2, 2025, Knowledge Ecology International (KEI) offered comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same”… Continue Reading
On May 7, 2025, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform” (90 FR 16878) to… Continue Reading
The USTR Special 301 Committee presented KEI with four questions in follow-up to our earlier comments. Below are the questions and KEI’s responses, also available as PDF: KEI-Responses-to-Hearing-Questions-2025-Special-301 KEI Responses to Hearing Questions – 2025 Special 301 Review (docket number… Continue Reading
Introduction In January 2025, the National Institutes of Health (NIH) introduced a new NIH Intramural Research Program Access Planning Policy (“IRP Access Planning Policy” or “Policy”). An NIH web page provides links to several documents describing the policy: https://osp.od.nih.gov/policies/innovation-and-translation#tab1/ The… Continue Reading
On December 26, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Anti-KK-LC-1 T Cell Receptors for the Treatment of Cancer” (89 FR 99888) to StraightLine… Continue Reading
On December 17, 2025, Knowledge Ecology International (KEI) provided comments to the National Institutes for Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Tumor Infiltrating Lymphocytes for the Treatment of Cancer” (89 FR 95224) to… Continue Reading